Recent Pullback Buying Opportunity For Blood Cancer Firm Geron: Goldman Sachs
Portfolio Pulse from Vandana Singh
Goldman Sachs has upgraded Geron Corporation (GERN) to Buy from Neutral, with a price target of $4. The FDA has assigned a standard review and a PDUFA action date of June 16, 2024, for Geron's New Drug Application for imetelstat. The FDA plans to hold an advisory committee meeting. The recent approval of Bristol-Myers Squibb & Co's Reblozyl does not negate the opportunity for imetelstat. The recent pullback in GERN shares has presented a buying opportunity.
September 12, 2023 | 6:43 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
The recent approval of Bristol-Myers Squibb & Co's Reblozyl does not negate the opportunity for Geron's imetelstat, suggesting a neutral impact on BMY.
The recent approval of Bristol-Myers Squibb & Co's Reblozyl does not negate the opportunity for Geron's imetelstat. This suggests that the impact on BMY's stock is neutral.
CONFIDENCE 80
IMPORTANCE 50
RELEVANCE 50
POSITIVE IMPACT
Goldman Sachs has upgraded Geron Corporation to Buy from Neutral, indicating a positive outlook for the company. The FDA's standard review for Geron's new drug, imetelstat, also suggests potential growth.
The upgrade by Goldman Sachs indicates a positive outlook for Geron Corporation. The FDA's standard review for Geron's new drug, imetelstat, suggests potential growth for the company. This, combined with the recent pullback in GERN shares, presents a buying opportunity.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100